Vertex is a global biotechnology company that discovers, develops, and commercializes transformative medicines for serious diseases in specialty markets by combining advances in disease understanding with therapeutic science. The company generates revenue from an approved portfolio spanning cystic fibrosis (five CFTR modulators), gene-edited cell therapies for sickle cell disease and beta thalassemia, and acute pain relief, while advancing a clinical pipeline targeting kidney diseases, neuropathic pain, type 1 diabetes, and other serious conditions through partnerships and acquisitions. Vertex distributes its medicines through specialty pharmacies and wholesalers globally, supports patient access through insurance navigation and co-pay assistance programs, and focuses on validated biological targets with predictive biomarkers and rapid regulatory pathways.